Get started

Zydus Therapeutics Inc. (United States)

Homepage: zydustx.com
Alternate names: Zydus Therapeutics, Zydus Therapeutics Inc.
ROR: 00s51q652
OpenAlex ID: I4405267004
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)
2022 · Deven V. Parmar, Kevinkumar A. Kansagra, et al. · Clinical Pharmacology in Drug Development · 94
PDF
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)
2022 · Dhananjai Agrawal, Deepak Varade, et al. · American Journal of Nephrology · 49
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis
2023 · Mohammad Shadab Siddiqui, Deven Parmar, et al. · Clinical Gastroenterology and Hepatology · 47
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY‐IL1 in Three Patients with Cryopyrin‐Associated Periodic Syndromes
2023 · Pravin Hissaria, Kevinkumar Kansagra, et al. · Clinical Pharmacology in Drug Development · 32
PDF
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India
2021 · Satheesh Chiradoni Thungappa, Tanveer Maksud, et al. · Clinical Breast Cancer · 27
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
2023 · Mohammad Shadab Siddiqui, Deven Parmar, et al. · Liver Transplantation · 20
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
2022 · Rene Rodriguez-Gutierrez, Jose Gerardo González, et al. · Journal of Lipid Research · 15
PDF
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
2026 · Cynthia Levy, Ana Lleo, et al. · Journal of Hepatology · 11
Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
2024 · Raj Vuppalanchi, Mary M. Cruz, et al. · Clinical Pharmacology & Therapeutics · 10
PDF
A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis
2025 · Amit Yeole, Laxmi Khanna, et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 9
Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease
2025 · Harpreet Kaur, Nilesh Pandey, et al. · Experimental Neurology · 6
PDF
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer
2024 · Rushabh Kothari, Maulik Doshi, et al. · Clinical Breast Cancer · 6
PDF
Simultaneous Estimation of Zy-19489 and Its Active Metabolitezy-20486 in Human Plasma Using Lc–Ms/Ms, a Novel Antimalarial Compound
2021 · Ashok M Ghoghari, Harilal V Patel, et al. · Bioanalysis · 3
Pharmacokinetics and Safety Evaluation of Single‐Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment
2023 · Eric Lawitz, Deven Parmar, et al. · Clinical Pharmacology in Drug Development · 2
PDF
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation
2026 · Mayank Gangwar, Gunjan Kumar, et al. · Trials · 1
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants
2023 · Kevinkumar A. Kansagra, Taufik Momin, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 1
A Food‐Effect Study to Evaluate the Oral Bioavailability of Desidustat
2022 · Hardik Patel, Taufik Momin, et al. · Clinical Pharmacology in Drug Development · 1
A phase 2b/3 trial of saroglitazar in primary biliary cholangitis
2026 · Raj Vuppalanchi, Alejandra Villamil, et al. · Hepatology
Saroglitazar improves hepatic steatosis and liver enzymes in women with polycystic ovary syndrome and MASLD: A multicenter, double-blind, placebo-controlled study
2026 · Niharika Samala, José González-González, et al. · Hepatology
A sensitive assay for estimation of DM1 fortified with trastuzumab in human serum utilizing positive LC-MS/MS electrospray ionization and its application to clinical study
2026 · Ashok Ghoghari, Harilal Patel, et al. · Bioanalysis
Fostering Clinical Pharmacology and Drug Development in India: A Perspective From SAC‐ACCP
2026 · Karthik Venkatakrishnan, Abhigyan Ravula, et al. · The Journal of Clinical Pharmacology
PDF
A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease
2026 · Mohit Desai, Bhargav Solanki, et al. · European Journal Of Haematology
PDF
Wcn26-390 a Phase-4, 52-week, Single Arm, Post-marketing Surveillance to Evaluate Safety of Desidustat for Treatment of Anemia in Subjects With Chronic Kidney Disease
2026 · Prakash Khetan, Hardik Shah, et al. · Kidney International Reports
A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular Degeneration
2026 · Mudit Bansal, Punit Singh, et al. · Ophthalmology and Therapy
PDF
SAT-668 Saroglitazar Improves Hepatic Steatosis And Liver Enzymes In Women With PCOS And MASLD: Results Of Evidences VII Randomized Control Study
2025 · Deven Parmar, Niharika Samala, et al. · Journal of the Endocrine Society
PDF
Works count: 31
Citation count: 570
Year
Topic
Type